Background: Core outcome sets (COS) are consensus-driven sets of minimum outcomes that should be measured and reported in all clinical trials. COS aim to reduce heterogeneity in outcome measurement and reporting, and selective outcome reporting. Implementing COS into clinical trials is challenging. Guidance to improve COS uptake in dermatology is lacking. Objectives: To develop a structured practical guide to COS implementation. Methods: Members of the Harmonising Outcome Measurement for Eczema (HOME) executive committee developed an expert opinion-based roadmap founded on a combination of a review of the COS implementation literature, the Core Outcome Measures in Effectiveness Trials (COMET) initiative resources, input from HOME members and experience in COS development and clinical trials. Results: The data review and input from HOME members was synthesized into themes, which guided roadmap development: (a) barriers and facilitators to COS uptake based on stakeholder awareness/engagement and COS features; and (b) key implementation science principles (assessment-driven, data-centred, priority-based and context-sensitive). The HOME implementation roadmap follows three stages. Firstly, the COS uptake scope and goals need to be defined. Secondly, during COS development, preparation for future implementation is supported by establishing the COS as a credible evidence-informed consensus by applying robust COS development methodology, engaging multiple stakeholders, fostering sustained and global engagement, emphasizing COS ease of use and universal applicability, and providing recommendations on COS use. Thirdly, incorporating completed COS into primary (trials) and secondary (reviews) research is an iterative process starting with mapping COS uptake and stakeholders’ attitudes, followed by designing and carrying out targeted implementation projects. Main themes for implementation projects identified at HOME are stakeholder awareness/engagement; universal applicability for different populations; and improving ease-of-use by reducing administrative and study burden. Formal implementation frameworks can be used to identify implementation barriers/facilitators and to design implementation strategies. The effect of these strategies on uptake should be evaluated and implementation plans adjusted accordingly. Conclusions: COS can improve the quality and applicability of research and, so, clinical practice but can only succeed if used and reported consistently. The HOME implementation roadmap is an extension of the original HOME roadmap for COS development and provides a pragmatic framework to develop COS implementation strategies.
19 August 2024 in Journal of the European Academy of Dermatology and Venereology
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed to maximize its uptake. Objectives: To provide answers to some of the commonly asked questions about using the HOME COS; to provide data to help with the interpretation of trial results; and to support sample size calculations for future trials. Methods and results: We provide practical guidance on the use of the HOME COS for investigators planning clinical trials in patients with AD. It answers some of the common questions about using the HOME COS, how to access the outcome measurement instruments, what training/resources are needed to use them appropriately and clarifies when the COS is applicable. We also provide exemplar data to inform sample size calculations for eczema trials and encourage standardized data collection and reporting of the COS. Conclusions: By encouraging adoption of the COS and facilitating consistent reporting of outcome data, it is hoped that the results of eczema trials will be more comprehensive and readily combined in meta-analyses and that patient care will subsequently be improved.
22 January 2025 in Journal of the European Academy of Dermatology and Venereology
The Harmonising Outcomes Measurement in Eczema (HOME) initiative developed a core outcome set (COS) for atopic dermatitis (AD), but uptake in trials is still limited. An online survey was sent out to corresponding authors of AD interventional randomized clinical trials to assess their awareness of the HOME COS, evaluate barriers to uptake and identify facilitators to enhance implementation. Survey respondents emphasized increasing awareness of the COS in the research community, reducing the burden associated with using the COS and ensuring applicability to diverse populations.
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set for atopic dermatitis (AD) clinical trials, including four core outcome domains: clinician-reported signs, patient-reported symptoms, eczema control and quality of life. For eczema control, the Atopic Dermatitis Control Tool (ADCT) and the Recap of Atopic Eczema (RECAP) were chosen through consensus methods as equivalent instruments. Objectives: This study aimed to develop equations to map scores between ADCT and RECAP to facilitate inter-measurement comparison and data synthesis. Methods: Patients with AD completed the HOME core outcome set of instruments, including ADCT, RECAP, Dermatology Life Quality Index series, Peak Pruritus Numerical Rating Scale and Patient-Oriented Eczema Measure, during routine clinic visits. Clinicians assessed disease severity using the Investigator Global Assessment x Body Surface Area measure. Results: Among 50 participants, ADCT and RECAP were strongly correlated (Pearson’s correlation coefficient, r = 0.970). Four mapping models were evaluated: simple linear regression (SLR), SLR without intercept, square root transformation (SRT) and SRT without intercept. While the SRT no intercept model had the lowest root mean square error, it produced nonlinear confidence intervals and risked overfitting. The SLR no intercept model, with high predictive accuracy (R2 = 0.971) and interpretability, was selected as the primary approach. Two equations were derived to convert scores between ADCT and RECAP, enabling standardized comparisons. Conclusions: This study provides two equations for mapping between ADCT and RECAP, strengthening the HOME outcome measurement set and synthesizing the two measures for clinical and research purposes. Validation with larger, independent cohorts is warranted to confirm these findings.